Novo Nordisk's Alzheimer's drug trial fails to meet primary goal

Novo Nordisk shares dropped significantly after its Alzheimer's drug trial failed to meet its primary objective of slowing cognitive decline. The trial investigated semaglutide, the active ingredient in Ozempic and Wegovy, for Alzheimer's progression. While biomarkers showed improvement, disease progression was not delayed as hoped. Analysts had considered the trial a long shot, and Novo had described it as a "lottery ticket" before the results were announced.